XORTX Therapeutics: Pioneering New Therapies for Progressive Kidney Disease
XORTX is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADP …
Redefining Kidney Disease Through Strategic Collaborations
XORTX is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection as well as XRx-225 which is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, they are dedicated to developing medications to improve the quality of life and future health of patients.
For more information on XORTX Therapeutics Inc. (TSX.V: XRTX) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.
.jpg)
